Theaflavin ameliorates behavioral deficits, biochemical indices and monoamine transporters expression against subacute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mouse model of Parkinson's disease

Neuroscience

Volumn 218, Issue , 2012, Pages 257-267

  Anandhan, A ^a   Janakiraman, U ^a   Manivasagam, T ^a  

^a ANNAMALAI UNIVERSITY   (India)

Author keywords

Behavior; DAT; Oxidative stress; Parkinson's disease; Theaflavin

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; CATALASE; DIHYDROXYPHENYLACETIC ACID; DOPAMINE TRANSPORTER; GLUTATHIONE; GLUTATHIONE PEROXIDASE; HOMOVANILLIC ACID; SUPEROXIDE DISMUTASE; THEAFLAVIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE; VESICULAR MONOAMINE TRANSPORTER 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BEHAVIOR DISORDER; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE MODEL; ENZYME ANALYSIS; IMMUNOHISTOCHEMISTRY; LOCOMOTION; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; OPEN FIELD TEST; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; ROTAROD TEST; SUBSTANTIA NIGRA; WESTERN BLOTTING;

ANIMALS; BEHAVIOR, ANIMAL; BIFLAVONOIDS; BLOTTING, WESTERN; CATECHIN; DISEASE MODELS, ANIMAL; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED C57BL; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PARKINSONIAN DISORDERS; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 84863779700     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2012.05.039     Document Type: Article

References (69)

1. Abercrombie M. Estimation of nuclear population from microtome sections. Anat Rec 1946, 94:239-247.
2. Aebi H. Catalase in vitro. Methods Enzymol 1984, 105:121-126.
3. Ames B.N., Shigenaga M.K., Hagen T.M. Oxidants, antioxidants, and the degenerative diseases of aging. Proc Natl Acad Sci USA 1993, 90:7915-7922.
4. Bhattacharya A., Ghosal S., Bhattacharya S.K. Antioxidant effect of Withania somnifera glycowithanolides in chronic foot-shock stress-induced perturbations of oxidative free radical scavenging enzymes and lipid peroxidation in rat frontal cortex and striatum. J Ethnopharmacol 2001, 74:1-16.
5. Braak H., Del Tredici K., Rub U., de Vos R.A., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003, 24:197-211.
6. Cai F., Li C.R., Wu J.L., Chen J.G., Liu C., Min Q., Yu W., Ouyang C.H., Chen J.H. Theaflavin ameliorates cerebral ischemia-reperfusion injury in rats through its anti-inflammatory effect and modulation of STAT-1. Mediators Inflamm 2006, 2006:1-9.
7. Cassarino D.S., Fall C.P., Swerdlow R.H., Smith T.S., Halvorsen E.M., Miller S.W., Parks J.P., Parker W.D., Bennet J.P. Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease. Biochem. Biophys. Acta 1997, 1362:77-86.
8. Chan D.K.Y., Woo J., Ho S.C., Pang C.P., Law L.K., Ng P.W., Hung W.T., Kwok T., Hui E., Orr K., Leung M.F., Kay R. Genetic and environmental risk factors for Parkinson's disease in a Chinese population. J Neurol Neurosurg Psychiatry 1998, 65:781-794.
9. Chaturvedi R.K., Shukla S., Seth K., Chauhan S., Sinha C., Shukla Y., Agrawal A.K. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Neurobiol Dis 2006, 22:421-434.
10. Ciliax B.J., Heilman C., Demchyshyn L.L., Pristupa Z.B., Ince E., Hersch S.M., Niznik H.B., Levey A.I. The dopamine transporter: immunochemical characterization and localization in brain. J Neurosci 1995, 153:1714-1723.
11. Crabbe J.C., Metten P., Yu C.H., Schlumbohm J.P., Cameron A.J., Wahlsten D. Genotypic differences in ethanol sensitivity in two tests of motor incoordination. J Appl Physiol 2003, 95:1338-1351.
12. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
13. Del Zompo M., Piccardi M.P., Ruiu S., Quartu M., Gessa G.L., Vaccari A. Selective uptake into synaptic dopamine vesicles: possible involvement in MPTP neurotoxicity. Br J Pharmacol 1993, 109:411-414.
14. Dexter D.T., Carter C.J., Wells F.R., Javoy-Agid F., Agid Y., Lees A., Jenner P., Marsden C.D. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 1989, 52:381-389.
15. Dexter D.T., Holley A.E., Flitter W.D., Slater T.F., Wells F.R., Daniel S.E., Lees A.J., Jenner P., Marsden C.D. Increased levels of lipid hydroperoxides in the parkinsonia substania nigra: an HPLC and ESR study. Mov Disord 1994, 9:92-97.
16. Dufresne C.J., Farnworth E.R. A review of latest research findings on the health promotion properties of tea. J Nutr Biochem 2001, 7:404-421.
17. Erickson J.D., Schafer M.K., Bonner T.I., Eiden L.E., Weihe E. Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proc Natl Acad Sci USA 1996, 93:5166-5171.
18. Franklin K.B.J., Paxinos G. The mouse brain in stereotaxic coordinates 2007, Academic Press, London.
19. Fredriksson A., Archer T. MPTP-induced behavioural and biochemical deficits: a parametric analysis. J Neural Transm Park Dis Dement Sect 1994, 7:123-132.
20. Gainetdinov R.R., Fumagalli F., Jones S.R., Caron M.G. Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J Neurochem 1997, 69:1322-1335.
21. German D.C., Liang C.L., Manaye K.F., Lane K., Sonsalla P.K. Pharmacological inactivation of the vesicular monoamine transporter can enhance 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of midbrain dopaminergic neurons, but not locus coeruleus noradrenergic neurons. Neuroscience 2000, 101:1063-1069.
22. Goldberg N.R.S., Haack A.K., Lim N.S., Janson O.K., Meshul C.K. Dopaminergic and behavioral correlates of a progressive mouse model of Parkinson's disease. Neuroscience 2011, 180:256-271.
23. Grelle G., Otto A., Lorenz M., Frank R.F., Wanker E.E., Bieschke J. Black tea theaflavins inhibit formation of toxic amyloid-beta and alpha-synuclein fibrils. Biochemistry 2011, 50:10624-10636.
24. Heikkila R.E., Sonsalla P. The MPTP-treated mouse as a model of Parkinsonism: how good is it. Neurochem Int 1992, 20:299-303.
25. Jollow D.J., Mitchell J.R., Zampaglione N., Gillette J.R. Bromobenzene induced liver necrosis. Protective role of glutathione and evidence for 3,4-bromobenzene oxide as the hepatotoxic metabolite. Pharmacology 1974, 11:151-169.
26. Kreisler A., Gele P., Wiart J.F., Lhermitte M., Destee A., Bordet R. Lipid lowering drugs in the MPTP mouse model of Parkinson's disease: fenofibrate has a neuroprotective effect, whereas bezofibrate and HMG-CoA reductase inhibitors do not. Brain Res 2007, 1135:77-84.
27. Kurosaki R., Muramatsu Y., Watanabe H., Michimata M., Matsubara M., Imai Y., Araki T. Role of dopamine transporter against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice. Metab Brain Dis 2003, 18:139-146.
28. Leung L.K., Su Y., Chen R., Zhang Z., Huang Y., Chen Z.Y. Theaflavins in black tea and catechins in green tea are equally effective antioxidants. J Nutr 2001, 131:2248-2251.
29. Levites Y., Amit T., Youdim M.B.H., Mandel S. Involvement of protein kinase C activation and cell survival/cell cycle genes in green tea polyphenol (-)-epigallocatechin-3-gallate neuroprotective action. J Biol Chem 2002, 277:30574-30580.
30. Levites Y., Weinreb O., Maor G., Youdim M.B., Mandel S. Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration. J Neurochem 2001, 78:1073-1082.
31. Li S., Pu X.P. Neuroprotective effect of kaempferol against a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease. Biol Pharm Bull 2011, 34:1291-1296.
32. Lin A.M., Yang C.H., Ueng Y.F., Luh T.Y., Liu T.Y., Lay Y.P., Ho L.T. Differential effects of carboxyfullerene on MPP+/MPTP-induced neurotoxicity. Neurochem Int 2004, 44:99-105.
33. Liu Y., Roghani A., Edwards R.H. Gene transfer of a reserpine-sensitive mechanism of resistance to N-methyl-4-phenylpyridinium. Proc Natl Acad Sci USA 1992, 89:9074-9078.
34. Loke W.M., Proudfoot J.M., Hodgson J.M., McKinley A.J., Hime N., Magat M., Stocker R., Croft K.D. Specific dietary polyphenols attenuate atherosclerosis in apolipoprotein E-knockout mice by alleviating inflammation and endothelial dysfunction. Arterioscler Thromb Vasc Biol 2010, 30:749-757.
35. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 1951, 193:265-275.
36. Luczaj W., Skrzydlewska E. Antioxidant properties of black tea in alcohol intoxication. Food Chem Toxicol 2004, 42:2045-2051.
37. Malagelada C., Jin Z., Jackson-Lewis V., Przedborski S., Greene L. Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease. J Neurosci 2010, 30:1166-1175.
38. Mandel S.A., Amit T., Kalfon L., Reznichenko L., Youdim M.B. Targeting multiple neurodegenerative diseases etiologies with multimodal-acting green tea catechins. J Nutr 2008, 138:1578-1583.
39. Meissner W., Hill M.O., Tison F., Gross C.E., Bezard E. Neuroprotective strategies for Parkinson's disease: conceptual limits of animal models and clinical trials. Trends Pharmacol Sci 2004, 25:249-253.
40. Miller G.W., Erickson J.D., Perez J.T., Penl S.N., Mash D.C., Rye D.B., Levey A.I. Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease. Exp Neurol 1999, 156:138-148.
41. Miller N.J., Castelluccio C., Tijburg L., Rice-Evans C. The antioxidant properties of theaflavins and their gallate esters: radical scavengers or metal chelators?. FEBS Lett 1996, 392:40-44.
42. Muralikrishnan D., Mohanakumar K.P. Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. FASEB J 1998, 12:905-912.
43. Oberley L.W., Spitz D.R. Assay of superoxide dismutase activity in tumor tissue. Methods Enzymol 1984, 105:457-464.
44. Przedborski S., Jackson-Lewis V., Djaldetti R., Liberatore G., Vila M., Vukosavic S., Almer G. The parkinsonian toxin MPTP: action and mechanism. Restor Neurol Neurosci 2000, 16:135-142.
45. RajaSankar S., Manivasagam T., Surendran S. Ashwagandha leaf extract: a potential agent in treating oxidative damage and physiological abnormalities seen in a mouse model of Parkinson's disease. Neurosci Lett 2009, 454:11-15.
46. Ramassamy C. Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: a review of their intracellular targets. Eur J Pharmacol 2006, 545:51-64.
47. Ranjith-Kumar C.T., Lai Y., Sarisky R.T., Cheng Kao C. Green tea catechin, epigallocatechin gallate, suppresses signaling by the dsRNA innate immune receptor RIG-I. PLoS ONE 2010, 5:e12878.
48. + administration to mice. Pharmacol Toxicol 1993, 72:364-368.
49. Rozas G., Lopez-Martin E., Guerra M.J., Labandeira-Garcia J.L. The overall rod performance test in the MPTP-treated mouse model of Parkinsonism. J Neurosci Methods 1998, 83:165-175.
50. Shiraki M., Hara Y., Osawa T., Kumon H., Nakayama T., Kawakishi S. Antioxidative and antimutagenic effects of theaflavins from black tea. Mutat Res 1994, 323:29-34.
51. Sil H., Sen T., Moulik S., Chatterjee A. Black tea polyphenol (theaflavin) downregulates MMP-2 in human melanoma cell line A375 by involving multiple regulatory molecules. J Environ Pathol Toxicol Oncol 2010, 29:55-68.
52. Skrzypczak-Jankun E., Jankun J. Theaflavin digallate inactivates plasminogen activator inhibitor: could tea help in Alzheimer's disease and obesity. Int J Mol Med 2010, 26:45-50.
53. Smeyne R.J., Jackson-Lewis V. The MPTP model of Parkinson's disease. Brain Res Mol Brain Res 2005, 134:57-66.
54. Spencer J.P.E. Flavonoids and brain health: multiple effects underpinned by common mechanisms. Genes Nutr 2009, 4:243-250.
55. Sun A.Y., Wang Q., Simonyi A., Sun G.Y. Resveratrol as a therapeutic agent for neurodegenerative diseases. Mol Neurobiol 2010, 41:375-383.
56. Tan E.K., Tan C., Fook-Chong S.M., Lum S.Y., Chai A., Chung H., Shen H., Zhao Y., Teoh M.L., Yih Y., Pavanni R., Chandran V.R., Wong M.C. Dose-dependent protective effect of coffee, tea, and smoking in Parkinson's disease: a study in ethnic Chinese. JNeurol Sci 2003, 216:163-167.
57. Tan L.C., Koh W.P., Yuan J.M., Wang R., Au W.L., Tan J.H., Tan E.K., Yu M.C. Differential effects of black versus green tea on risk of Parkinson's disease in the Singapore Chinese Health Study. Am J Epidemiol 2008, 167:553-560.
58. Thiffault C., Anumoun N., Quirion R., Poirier J. Effect of MPTP and l-deprenyl on antioxidant enzymes and lipid peroxidation levels in mouse brain. J Neurochem 1995, 65:2725-2733.
59. Thomas T., Timmer M., Cesnulevicius K., Hitti E., Kotlyarov A., Gaestel M. MAPKAP kinase 2-deficiency prevents neurons from cell death by reducing neuroinflammation-relevance in a mouse model of Parkinson's disease. J Neurochem 2008, 105:2039-2052.
60. Tillerson J.L., Miller G.W. Grid performance test to measure behavioral impairment in the MPTP-treated mouse model of Parkinsonism. J Neurosci Methods 2003, 123:189-200.
61. Toffa S., Kunikowska G.M., Zeng B.Y., Jenner P., Marsden C.D. Glutathione depletion in rat brain does not cause nigrostriatal pathway degeneration. J Neural Transm 1997, 104:67-75.
62. Trautwein E.A., Du Y., Meynen E., Yan X., Wen Y., Wang H., Molhuizen H.O. Purified black tea theaflavins and theaflavins/catechin supplements did not affect serum lipids in healthy individuals with mildly to moderately elevated cholesterol concentrations. Eur J Nutr 2010, 49:27-35.
63. Weihe E., Eiden L.E. Chemical neuroanatomy of the vesicular amine transporters. FASEB J 2000, 14:2435-2449.
64. Weinreb O., Amit T., Mandel S., Youdim M.B. Neuroprotective molecular mechanisms of (-)-epigallocatechin-3-gallate: a reflective outcome of its antioxidant, iron chelating and neuritogenic properties. Genes Nutr 2009, 4:283-296.
65. Wright A.M., Bempong J., Kirby M.L., Barlow R.L., Bloomquist J.R. Effects of haloperidol metabolites on neurotransmitter uptake and release: possible role in neurotoxicity and tardive dyskinesia. Brain Res 1998, 788:215-222.
66. Yamamoto Y., Takahashi K. Glutathione peroxidase isolated from plasma reduces phospholipid hydroperoxide. Arch Biochem Biophys 1993, 305:541-545.
67. Zang L.Y., Misra H.P. Generation of reactive oxygen species during the monoamine oxidase catalysed oxidation of the neurotoxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Biol Chem 1993, 268:16504-16512.
68. Zarow C., Lyness S.A., Mortimer J.A., Chui H.C. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol 2003, 60:337-341.
69. Zhou C., Huang Y., Przedborski S. Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance. Ann N Y Acad Sci 2008, 1147:93-104.